ACADIA Pharmaceuticals's Return On Capital Employed Insights

By: via Benzinga
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up ...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.